Tricida
General Information | |
Business: |
Our goal is to slow the progression of chronic kidney disease, or CKD, through the treatment of metabolic acidosis. We are a late-stage pharmaceutical company focused on the development and commercialization of our drug candidate, TRC101, a non-absorbed polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal, or GI, tract. We recently completed our pivotal Phase 3 clinical trial, TRCA-301, that met both its primary and secondary endpoints in a highly statistically significant manner (p<0.0001 for all primary and secondary endpoints).
|
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 61 |
Founded: | 2013 |
Contact Information | |
Address | 7000 Shoreline Court Suite 201, South San Francisco, CA 94080, US |
Phone Number | (415) 429-7800 |
Web Address | http://ricida.com |
View Prospectus: | Tricida |
Financial Information | |
Market Cap | $659.4mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-59.7 mil (last 12 months) |
IPO Profile | |
Symbol | TCDA |
Exchange | NASDAQ |
Shares (millions): | 11.7 |
Price range | $19.00 - $19.00 |
Est. $ Volume | $222.3 mil |
Manager / Joint Managers | Goldman Sachs/ J.P. Morgan/ Cowen |
CO-Managers | - |
Expected To Trade: | 6/28/2018 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |